Furiex Pharmaceuticals (FURX) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 28, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Furiex Pharmaceuticals, Inc.	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	10,609,662	'
Entity Public Float	'	'	$249,700,000
Amendment Flag	'false	'	'
Entity Central Index Key	'0001484478	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Revenue:	'		'		'
Milestones	$45,000		$20,000		'
Royalties	25,999		20,508		4,490
Total revenue	70,999	[1]	40,508	[2]	4,490
Research and development expenses	82,704		69,505		44,202
Selling, general and administrative expenses	12,676		11,261		8,761
Depreciation and amortization	57		86		83
Total operating expenses	95,437		80,852		53,046
Operating loss	-24,438		-40,344		-48,556
Interest expense	4,980		2,508		413
Other income, net	93		1		2
Loss before provision for income taxes	-29,325		-42,851		-48,967
Less provision for income taxes	348		14		14
Net loss	($29,673)		($42,865)		($48,981)
Net loss per basic and diluted share (in Dollars per share)	($2.92)		($4.29)		($4.96)
Weighted-average shares used to compute net loss per basic and diluted share: (in Shares)	10,148		9,984		9,884
[1]	The first quarter of 2013 includes a $25.0 million regulatory milestone from Takeda with respect to the FDA approval of three new alogliptin-related products in January 2013 and a $5.0 million milestone from Menarini upon the launch of Priligy in France in March 2013. The third quarter of 2013 includes a $10.0 million milestone from Takeda upon the European Marketing Authorization of alogliptin and related products in September 2013. The fourth quarter of 2013 includes a $5.0 million milestone from Menarini upon the launch of Priligy in the United Kingdom in October 2013.
[2]	The second quarter of 2012 includes a $10.0 million regulatory milestone related to the acceptance of the submission of a Marketing Authorization Application by the European Medicines Agency for alogliptin in May 2012. The third quarter of 2012 includes a $10.0 million launch-based milestone related to the Priligy license agreement with Menarini.

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$29,153	$25,718
Accounts receivable, net	8,178	11,745
Prepaid expenses	415	320
Total current assets	37,746	37,783
Property and equipment, net	87	118
Investments	'	7,500
Deferred financing costs, net	1,493	238
Goodwill	49,116	49,116
Total assets	88,442	94,755
Current liabilities:	'	'
Accounts payable	7,072	6,604
Accrued expenses	5,302	10,230
Current portion of long-term debt, third party	10,080	5,405
Current portion of long-term debt, related party	500	'
Total current liabilities	22,954	22,239
Long-term debt, third party, net	31,920	34,595
Long-term debt, related party, net	14,500	'
Other long-term liabilities	627	324
Total liabilities	70,001	57,158
Commitments and contingencies (Note 11)	'	'
Common stock, $0.001 par value, 40,000,000 shares authorized; 10,015,297 and 10,459,233 shares issued and outstanding, respectively	10	10
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued or outstanding	'	'
Paid-in capital	175,094	164,577
Accumulated deficit	-156,663	-126,990
Total shareholders’ equity	18,441	37,597
Total liabilities and shareholders’ equity	$88,442	$94,755

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	10,459,233	10,015,297
Common stock, shares outstanding	10,459,233	10,015,297
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
In Thousands
Balance at at Dec. 31, 2010	$10	$153,638	($35,144)	$118,504
Balance at (in Shares) at Dec. 31, 2010	9,881	'	'	'
Exercise of common stock options	'	620	'	620
Exercise of common stock options (in Shares)	68	'	'	'
Share based compensation expense	'	4,180	'	4,180
Net loss	'	'	-48,981	-48,981
Balance at at Dec. 31, 2011	10	158,438	-84,125	74,323
Balance at (in Shares) at Dec. 31, 2011	9,949	'	'	'
Exercise of common stock options	'	600	'	600
Exercise of common stock options (in Shares)	66	'	'	'
Share based compensation expense	'	5,539	'	5,539
Net loss	'	'	-42,865	-42,865
Balance at at Dec. 31, 2012	10	164,577	-126,990	37,597
Balance at (in Shares) at Dec. 31, 2012	10,015	'	'	'
Exercise of common stock options	'	3,615	'	3,615
Exercise of common stock options (in Shares)	307	'	'	'
Issuance of restricted stock (in Shares)	137	'	'	'
Share based compensation expense	'	6,902	'	6,902
Net loss	'	'	-29,673	-29,673
Balance at at Dec. 31, 2013	$10	$175,094	($156,663)	$18,441
Balance at (in Shares) at Dec. 31, 2013	10,459	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net loss	($29,673)	($42,865)	($48,981)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	57	86	83
Amortization of deferred financing costs	260	62	'
Share based compensation expense	6,902	5,539	4,180
Changes in operating assets and liabilities:	'	'	'
Accounts receivable, net	3,567	-9,760	-1,726
Prepaid expenses and other current assets	-95	-106	752
Accounts payable	468	6,511	-3
Accrued expenses	-4,928	-192	-3,345
Other long-term liabilities	303	92	40
Net cash used in operating activities	-23,139	-40,633	-49,000
Cash flows from investing activities:	'	'	'
Purchases of property and equipment	-26	-77	-22
Purchases of investments	'	-7,500	-10,000
Proceeds from sale of investments	7,500	10,000	'
Net cash (used in) provided by investing activities	7,474	2,423	-10,022
Cash flows from financing activities:	'	'	'
Proceeds from borrowings on long-term debt	19,162	30,000	10,000
Repayments of long-term debt	-2,162	'	'
Debt issuance costs	-1,515	-300	'
Proceeds from issuance of common stock	3,615	600	620
Net cash provided by financing activities	19,100	30,300	10,620
Net (decrease) increase in cash and cash equivalents	3,435	-7,910	-48,402
Cash and cash equivalents, beginning of the period	25,718	33,628	82,030
Cash and cash equivalents, end of the period	29,153	25,718	33,628
Supplemental Disclosure of Cash Flow Information:	'	'	'
Interest paid	4,151	2,020	299
Taxes paid	$330	'	'

Note_1_Summary_of_Operations_a

Note 1 - Summary of Operations and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	'
	1.    Summary of Operations and Significant Accounting Policies
	Organization and Business Description
	Furiex Pharmaceuticals, Inc., a Delaware corporation (“Furiex” or the “Company”), is a drug development company that continues the compound partnering business started by Pharmaceutical Product Development, Inc. (“PPD”) in 1998. On June 14, 2010, PPD effected the spin-off of Furiex through a tax-free, pro-rata dividend distribution of all of the shares of the Company to PPD shareholders. The goal of the Company is to in-license compounds from, or form strategic alliances with, pharmaceutical and biotechnology companies to share the risks and rewards of developing therapeutics. The Company's operations are headquartered in Morrisville, North Carolina.
	The Company has incurred losses and negative cash flows from operations since the spin-off and expects to continue to incur operating losses until revenues from all sources reach a level sufficient to support its on-going operations. The Company’s liquidity will largely be determined by its ability to raise capital from debt, equity, or other forms of financing, by the success of its products already being commercialized by collaborators, by key development and regulatory events that might impact its ability to out-license its development compounds, by its ability to enter into new collaborations and their terms, and by expenses associated with operations including research and development and potential commercialization efforts.
	The Company’s liquidity over the next 12 months could be materially affected by, among other things: its ability to raise additional funds through debt, equity or other financing alternatives; costs related to its development and potential commercialization efforts; regulatory approval and commercialization of its compound candidates, which could affect selling, general and administrative expenses and milestone and royalty receipts; changes in regulatory compliance requirements; reliance on existing collaborators and potential need to enter into additional collaborative arrangements; and other factors. Depending upon the success and timing of potential new collaborations or potential commercialization efforts and receipt of various milestone payments and royalties, it might be necessary to do one or more of the following in the next 12 months: (a) raise additional capital through equity or debt financings or from other sources; (b) reduce spending on research and development and/or commercialization of eluxadoline; or (c) restructure the Company's operations. The Company currently receives on-going revenue from royalties on sales of Nesina® and related combination products, as well as Priligy®.
	Principles of Consolidation
	The Company prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, and they include the accounts of Furiex Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Use of Estimates in Preparation of the Financial Statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Earnings Per Share
	The Company calculates net income (loss) per basic share by dividing net income (loss) by the weighted-average number of shares outstanding during the reporting period. The Company calculates net income (loss) per diluted share by dividing net income (loss) by the weighted-average number of shares outstanding during the reporting period plus the effects of any dilutive common stock-based awards. All potentially dilutive securities relate to stock options and restricted stock awards issued as part of the Company's share-based compensation plan. The calculation of net loss per diluted share for the years ended December 31, 2011, 2012 and 2013 is the same as net loss per basic share because the inclusion of any potentially dilutive securities would be anti-dilutive. Potentially dilutive securities totaling approximately 1,511,000, 1,644,000 and 1,472,000 for the years ended December 31, 2011, 2012 and 2013, respectively, were excluded from the calculation of diluted loss per share because of their anti-dilutive effect.
	Comprehensive Income (Loss)
	There are no items of comprehensive loss other than net loss for any periods presented.
	Revenue Recognition
	The Company generates revenue in the form of upfront payments, development and regulatory milestone payments, royalties, and launch-based and sales-based milestone payments in connection with the out-license or sale of products. The receipt of future milestone payments and royalties depends on the success of the Company's compound development and the Company's collaborators' success in developing and commercializing compounds. Upfront payments are generally paid within a short period of time following the execution of an out-license or collaboration agreement. Development and regulatory milestone payments are typically one-time payments to the Company triggered by the collaborator's achievement of specified development and regulatory events such as the commencement of Phase III trials or regulatory submission approval. Royalties are payments received by the Company based on net product sales of a collaborator. Launch-based milestone payments are one-time payments to the Company triggered when a collaborator first introduces for sale an out-licensed product in a new geographical region. Sales-based milestone payments are typically one-time payments to the Company triggered when aggregate net sales of product by a collaborator for a specified period (for example, an annual period) reach an agreed upon threshold amount. The Company recognizes upfront payments, development and regulatory milestone payments, royalty payments, and launch-based and sales-based milestone payments from its collaborators when the event that triggers the obligation of payment has occurred, there is no further obligation on the Company's part in connection with the payment and collection is reasonably assured.
	The Company assesses each collaboration agreement it enters into for potential indicators associated with agent and principal considerations for each related cash payment and receipt. Based on the terms of the underlying agreement and the determination of which party to the transaction is the primary obligor, the Company records the underlying activities that are associated with contractual payments within the consolidated statements of operations and consolidated balance sheets on a net or gross basis, accordingly.
	Concentration of Credit Risk
	The Company's collaborators, which are its current sources of revenue, are primarily pharmaceutical companies. A concentration of credit risk with respect to revenue exists due to the small number of collaborators. Three collaborators accounted for all of the Company's revenue for the years ended December 31, 2011, 2012 and 2013. The first collaborator accounted for $3.6 million, $28.1 million and $58.7 million of total revenue for the years ended December 31, 2011, 2012 and 2013, respectively. The second collaborator accounted for $0.8 million, $2.4 million and $0.6 million of total revenue for the years ended December 31, 2011, 2012 and 2013, respectively. The third collaborator accounted for $10.0 million and $11.7 million of total revenue for the years ended December 31, 2012 and 2013, respectively. The Company had no revenue from the third collaborator for the year ended December 31, 2011.
	Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and accounts receivable. All of the Company's cash is held in deposit accounts at a major financial institution, which management assesses to be of high credit quality. The Company’s money market fund investments (categorized as cash and cash equivalents) are with what the Company believes are high quality issuers. The Company has not experienced any losses in such accounts.
	The December 31, 2012 and 2013 balance of accounts receivable relates to royalty receivables related to Nesina and its combination products and Priligy based on net product sales and activities by the Company's collaborators and, as described in Note 11, amounts due from a collaborator to fund on-going clinical study costs associated with Priligy. The first, second and third collaborator accounted for $8.0 million, $2.0 million and $1.7 million, respectively, of the accounts receivable balance as of December 31, 2012. The first, second and third collaborator accounted for $7.5 million, $0.1 million and $0.6 million, respectively, of the accounts receivable balance as of December 31, 2013.
	Research and Development Expenses
	Research and development costs consist primarily of costs associated with pre-clinical studies, non-clinical studies and the clinical trials of the Company's compounds, development materials, labor and related benefit charges associated with personnel performing research and development work, supplies associated with this work and consulting services. Research and development costs include clinical research services, pre-clinical testing, non-clinical testing and clinical drug manufacturing provided by third parties, the direct cost of the Company's personnel managing the programs and upfront and milestone payments to the Company's collaborators. The Company accrues certain costs related to clinical studies, including investigative site payments, based on estimates of the services performed and efforts expended. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual accordingly. The Company charges research and development costs to operations as incurred and discloses them in the consolidated statements of operations.
	Income Taxes
	The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the year, plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial reporting and tax basis of the Company's assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when enacted.
	Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment, including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. Due to the historical losses from the Company's operations, a full valuation allowance on deferred tax assets has been recorded.
	Share-Based Compensation
	The Company recognizes compensation expense using a fair-value based method related to stock options, restricted stock awards and other share-based compensation. The expense is measured based on the grant date fair value of the awards that are expected to vest and is recorded over the applicable requisite service period. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate.
	Goodwill
	The Company records as goodwill the excess of the purchase price of a business acquired over the fair value of net tangible assets and identifiable intangible assets at the date of the acquisition. The Company evaluates goodwill for impairment on an annual basis each October 1 or more frequently if events or changes in circumstances indicate that goodwill might be impaired. Any impairment could have a material adverse effect on the Company's financial condition and results of operations.
	Cash, Cash Equivalents, and Investments
	Cash and cash equivalents consist of unrestricted cash accounts and money market funds that hold short-term U.S. Treasury securities that are not subject to withdrawal restrictions or penalties. The Company considers all cash on deposit and money market accounts with original maturities of three months or less at time of purchase to be cash and cash equivalents.
	Investments consisted of restricted cash accounts and money market funds that held short-term U.S. Treasury securities that were subject to contractual withdrawal restrictions and penalties. Under the Amended and Restated Loan and Security Agreement with Midcap Funding III, LLC, Midcap Funding RE Holdings, LLC and Silicon Valley Bank, the Company was required to maintain a minimum cash balance with Silicon Valley Bank. However, on September 30, 2013, the Company and its subsidiaries entered into a Second Amended and Restated Loan and Security Agreement with Midcap Funding III, LLC, Midcap Funding V, LLC and Silicon Valley Bank. Under the Second Amended and Restated Loan and Security Agreement, the Company is still required to maintain its primary deposit and investment accounts with Silicon Valley Bank, consisting of at least 50% of the Company's total cash and cash equivalents balance. However, the Second Amended and Restated Loan and Security Agreement does not require the Company to maintain a minimum cash balance.
	Property and Equipment
	The Company records property and equipment at cost less accumulated depreciation. The Company records depreciation using the straight-line method, based on the following estimated useful lives:
		Years
	Furniture and equipment		5	–	10
	Computer equipment and software		2	–	5
	Operating Leases
	The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The Company begins amortization on the date of initial possession, which is generally when the Company enters the space and begins to make improvements in preparation for its intended use. The Company accounts for the difference between rent expense and rent paid as deferred rent. The Company records a deferred rent liability at the inception of the lease term and amortizes the deferred rent over the term of the lease as a reduction to rent expense.

Note_2_Accounts_Receivable

Note 2 - Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	'
	2.    Accounts Receivable
	Accounts receivable consisted of the following amounts on the dates set forth below:
		December 31,
		2012		2013
	Royalties	$	10,045	$	8,147
	Priligy on-going clinical study costs (Note 11) and other		1,700		31
		$	11,745	$	8,178
	The Company did not record a provision for doubtful accounts as of December 31, 2012 or 2013 based on its assessment of collection risks. The December 31, 2012 and 2013 balance of accounts receivable relate to royalty receivables related to Nesina and related combination products and Priligy based on net product sales by the Company's collaborators and, as described in Note 11, amounts due from a collaborator to fund on-going clinical study costs associated with Priligy.

Note_3_Property_and_Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	3.    Property and Equipment
	Property and equipment, stated at cost, consisted of the following amounts on the dates set forth below:
		December 31,
		2012			2013
	Furniture and equipment	$	98		$	98
	Computer equipment and software		245			271
	Total property and equipment		343			369
	Less accumulated depreciation		(225	)		(282	)
	Total property and equipment, net	$	118		$	87
	There was no noncash investing activity related to liabilities that remain unpaid for the acquisition of property and equipment as of December 31, 2012 and 2013.

Note_4_Goodwill

Note 4 - Goodwill	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Goodwill Disclosure [Text Block]	'
	4.    Goodwill
	The Company reviews goodwill for impairment annually on October 1 and whenever events or changes in circumstances indicate that the carrying amount of goodwill might not be recoverable. There were no additions to goodwill for the years ended December 31, 2012 and 2013.
	The Company used the quantitative two-step goodwill impairment model as of the October 1, 2012 annual impairment test. This analysis utilized both the income and market approaches. For the income approach, the Company used a discounted cash flow method using the expected future inflows and outflows of the business and an appropriate discount rate. The market approach considered recent comparable transactional valuation multiples for pharmaceutical and biotechnology companies. Based on the review as of October 1, 2012, the Company's calculated fair value of its sole goodwill reporting unit was in significant excess of carrying value.
	As of the October 1, 2013 annual impairment test, the Company used the qualitative assessment of whether it is more likely than not that a reporting unit's fair value is less than its carrying value before applying the two-step goodwill impairment model. Based on the review as of October 1, 2013, the Company determined that its sole reporting unit's fair value was, more likely than not, greater than its carrying value. As such the quantitative two-step goodwill impairment model was not utilized.
	The fair value of goodwill could be materially impacted by future adverse changes such as future declines in operating results, a decline in the valuation of pharmaceutical and biotechnology company stocks, including the valuation of the Company's common stock, a slowdown in the worldwide economy or the pharmaceutical and biotechnology industry, failure to meet the performance projections included in forecasted operating results, or the delay or abandonment of any research and development programs.
	There are no accumulated impairment losses related to the Company’s recorded goodwill balance as of the years ended December 31, 2012 and 2013.

Note_5_Accrued_Expenses

Note 5 - Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	5.    Accrued Expenses
	Accrued expenses consisted of the following amounts on the dates set forth below:
		December 31,
		2012		2013
	Salaries, wages, benefits and related costs	$	1,181	$	1,315
	Research and development costs		3,143		3,057
	Professional fees		101		89
	Interest		344		634
	Janssen transition service payments (Note 11)		3,750		—
	Priligy on-going clinical study costs (Note 11)		1,700		207
	Other		11		—
		$	10,230	$	5,302

Note_6_LongTerm_Debt

Note 6 - Long-Term Debt	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Long-term Debt [Text Block]	'
	6.    Long-Term Debt
	Third Party Debt
	On August 18, 2011, the Company and its subsidiaries entered into a Loan and Security Agreement (the “Agreement”) with Midcap Funding III, LLC and Silicon Valley Bank. The initial borrowing in the amount of $10.0 million had a fixed interest rate of 10.25% per annum and was due August 1, 2015. Interest accrued monthly and was payable on the first day of the following month, in arrears. Principal payments of the initial borrowing were to be paid on a ratable monthly basis from August 1, 2012 until maturity. On August 2, 2012, the Company and its subsidiaries entered into an Amended and Restated Loan and Security Agreement (the “Amended Agreement”) with Midcap Funding III, LLC, Midcap Funding RE Holdings, LLC and Silicon Valley Bank. The Amended Agreement modified the prior Agreement by providing an additional $30.0 million in borrowings and reset the maturity date of the initial Agreement to August 2, 2016. On September 30, 2013, the Company and its subsidiaries entered into a Second Amended and Restated Loan and Security Agreement (the “Second Amended Agreement”) with Midcap Funding III, LLC, Midcap Funding V, LLC and Silicon Valley Bank, or collectively, the “Lenders”.
	The Second Amended Agreement modified the prior Amended Agreement by resetting the outside maturity date to October 1, 2018, deferring payment of any principal amounts until May 2014, and increased the total amount of the loan to $42.0 million. The Second Amended Agreement bears interest at a fixed rate of 10.00%. Interest accrues daily and is payable on the first day of the following month, in arrears.
	Principal payments under the Second Amended Agreement begin on May 15, 2014, with additional payments due on August 15, September 15, and November 15, 2014. Beginning on February 15, 2015 and continuing through and including the maturity date, principal payments are due each February, May, August and November. Beginning with the September 15, 2014 payment, the principal payments will consist of an amount equal to either 25% or 50% of the Company’s alogliptin royalties for the previous fiscal quarter, subject to minimum and maximum dollar amounts of payments ranging from a minimum of $1.26 million to a maximum of $4.20 million each quarter, dependent on whether the Company has submitted to the FDA a new drug application for eluxadoline.
	Under the Second Amended Agreement, the Company is required to maintain its primary deposit and investment accounts with Silicon Valley Bank, consisting of at least 50% of the Company's total cash and cash equivalents balance. The Company intends to use the proceeds from the loan to support research and development for its eluxadoline compound.
	A final payment fee is due to the Lenders in an amount equal to 3.5% of the total loan commitment, payable at the maturity date or upon prepayment of the loan. The Company may prepay the loan subject to a prepayment fee of between 2.0% and 3.5% of the amount borrowed, depending on the time of the prepayment. The amount of interest expense related to the initial Agreement, Amended Agreement and the Second Amended Agreement included in the statement of operations includes the ratable accrual of the final payment fee of $1.5 million and the amortization of deferred financing costs of $1.5 million over the term of the loan.
	Under the Second Amended Agreement, the Company and its subsidiaries are subject to affirmative covenants, including obligations to maintain good standing, provide certain notices to the Lenders, deliver financial statements to the Lenders, maintain insurance, discharge all taxes, protect intellectual property and protect collateral. The Company and its subsidiaries are also subject to negative covenants, including that each may not enter into a merger or consolidation or certain change of control events, incur liens on the collateral, incur additional indebtedness, dispose of any property, change its jurisdiction of organization or organizational structures or types, declare or pay dividends (other than dividends payable solely in common stock), make certain investments or acquisitions, and enter into certain transactions with affiliates, in each case subject to certain customary exceptions, including exceptions that allow the Company and its subsidiaries to acquire additional compounds and to enter into licenses and similar agreements providing for the use and collaboration of the Company's and its subsidiaries' intellectual property provided certain conditions are met. The obligations of the Company under the Second Amended Agreement are secured by a first priority lien on substantially all of the Company’s existing and after-acquired assets, excluding intellectual property (but including the proceeds thereof). The obligations of the Company and its subsidiaries under the Second Amended Agreement are also secured by a first priority lien on the equity interests of the Company in its subsidiaries.
	The Second Amended Agreement provides that events of default include failure to make payment of principal or interest on the loan when required, failure to perform certain obligations under the Second Amended Agreement and related documents, defaults in certain other indebtedness and certain other events including certain adverse actions taken by the FDA or other governmental authorities. Upon events of default, the Company's obligations under the Second Amended Agreement may, or in the event of insolvency or bankruptcy will automatically, be accelerated. Upon the occurrence of any event of default, the Company's obligations under the Second Amended Agreement will bear interest at a rate equal to the lesser of (a) 4% above the rate of interest applicable to such obligations immediately prior to the occurrence of the event of default or (b) the maximum rate allowable under law. As of December 31, 2013, the Company was in compliance with its obligations under the Second Amended Agreement.
	Related Party Debt
	On September 30, 2013, the Company and its subsidiaries entered into a Loan and Security Agreement with Fredric N. Eshelman, the Company’s chairman of the board and 27.2% stockholder, pursuant to which the Company borrowed $15.0 million (the “Eshelman Loan”). The Eshelman Loan becomes due and payable on the earlier of January 1, 2019 or 91 days after the Second Amended Agreement loan has been paid in full.
	The Eshelman Loan bears interest at a fixed rate of 9.00% per annum. Interest accrues daily and is payable on the first day of the following month, in arrears. Principal payments of $166,667 on the Eshelman Loan Agreement begin on October 1, 2014, and continue on a monthly basis thereafter through and including the maturity date, subject to the condition that, to the extent provided in the Subordination and Intercreditor Agreement with Midcap (the “Subordination Agreement”), if then in effect, the Company has $7.5 million of unrestricted cash on hand after giving effect to each such principal payment. The Company may prepay the Eshelman Loan without penalty or premium to the extent permitted under the Subordination Agreement. For the year ended December 31, 2013 $0.3 million of interest expense related to the Eshelman Loan was reflected in the consolidated statements of operations.
	The obligations of the Company and its subsidiaries under the Eshelman Loan Agreement are secured by a second priority lien on substantially all of the Company’s and its subsidiaries’ existing and after-acquired assets, excluding intellectual property (but including the proceeds thereof). The obligations of the Company and its subsidiaries under the Eshelman Loan Agreement are also secured by a second priority lien on the equity interests of the Company in its subsidiaries. The Eshelman Loan is subordinate to the Second Amended Agreement loan.
	Under the Eshelman Loan, the Company and its subsidiaries are subject to affirmative covenants substantially consistent to the Second Amended Agreement loan. The Eshelman Loan also has events of default that are substantially consistent to the Second Amended Agreement loan, except for upon occurrence of any event of default, the Company's obligations under the Eshelman Loan will bear interest at a rate equal to the lesser of (a) 3% above the rate of interest applicable to such obligations immediately prior to the occurrence of the event of default or (b) the maximum rate allowable under law. As of December 31, 2013, the Company was in compliance with its obligations under the Eshelman Loan.
	Current Portion of Long-Term Debt
	Per the terms of the Second Amended Agreement, the amounts of principal payments are dependent on the amounts of alogliptin royalties received by the Company, subject to minimum and maximum thresholds. Due to the variable nature of future principal payments, the Company has disclosed within its consolidated balance sheets the maximum amount that could be due within the next twelve months as current portion of long-term debt. In addition, the Eshelman Loan’s repayment timing is dependent upon the indebtedness under the Second Amended Agreement having been paid in full. As such, the current portion of long-term debt for this related party and third party loan are based on the maximum settlement amounts of the Second Amended Agreement loan. In addition, the following maturity tables are also based on the maximum settlement amounts for both the third party and related party loans.
	As of December 31, 2012 and 2013, third party long-term debt outstanding was as follows:
		December 31,
		2012			2013
	Total debt, third party	$	40,000		$	42,000
	Less current portion of long-term debt, third party		(5,405	)		(10,080	)
	Long-term debt, third party, net	$	34,595		$	31,920
	As of December 31, 2012 and 2013, related party long-term debt outstanding was as follows:
		December 31,
		2012			2013
	Total debt, related party	$	—		$	15,000
	Less current portion of long-term debt, related party		—			(500	)
	Long-term debt, related party, net	$	—		$	14,500
	As of December 31, 2013, maturities of third party debt for each of the next four years were as follows:
	2014	$	10,080
	2015		16,800
	2016		15,120
	2017		—
		$	42,000
	As of December 31, 2013, maturities of related party debt for each of the next four years were as follows:
	2014	$	500
	2015		2,000
	2016		2,000
	2017		10,500
		$	15,000

Note_7_Lease_Obligations

Note 7 - Lease Obligations	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	7.    Lease Obligations
	The Company is currently obligated under an operating lease and a sublease for two locations relating to office space and associated building expenses. One lease expires in December 2014 while the sublease expires in June 2014, with an optional renewal period for an additional year. As of December 31, 2013, future minimum payments for all lease obligations for the subsequent year were $0.08 million.
	Rental expense related to operating leases has been recorded in the consolidated statements of operations in the amounts of $0.2 million for each of the years ended December 31, 2011, 2012 and 2013, respectively.

Note_8_ShareBased_Compensation

Note 8 - Share-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	8.    Share-Based Compensation
	The Company has adopted an equity incentive plan, the Furiex Pharmaceuticals, Inc. 2010 Stock Plan, as amended (the “Plan”). The Company is authorized to issue a total of 2,178,641 shares under the Plan. The Plan is intended to provide incentives to employees, directors and consultants through the issuance of common stock-based awards, including restricted stock, stock options, stock appreciation rights and other equity-based awards. The plan is administered by a committee designated by its board of directors.
	Equity Compensation Plan – Stock Options
	During the years ended December 31, 2011 and 2012, the Company granted 742,234 and 198,000 stock options to employees, directors and consultants, with a weighted-average exercise price of $13.87 and $17.95, respectively. No stock options were granted during the year ended December 31, 2013. All options were granted with an exercise price equal to the fair value of the Company's common stock on the grant date. The fair value of the Company's common stock on the grant date is equal to the most recent NASDAQ closing price of the Company's stock.
	The Company recognizes compensation expense using a fair-value based method related to stock options and other share-based compensation. The expense is measured based on the grant date fair value of the awards that are expected to vest and is recorded over the applicable requisite service period on a straight-line basis. The options granted vest per one of the following schedules: (1) after a period of approximately one year (or less in the case of certain 2011 Director grants); (2) ratably over three years on the anniversary date of grant; or (3) one-third vest on grant date and the remaining ratably over two years on the anniversary date of grant. The options expire on the earlier of ten years from the date of grant, or within specified time limits following termination of employment, retirement or death. Shares are issued from authorized, but unissued stock. The Company does not pay dividends on unexercised options.
	The weighted-average grant date fair value per share was determined using the Black-Scholes option-pricing method. The weighted-average grant date fair value per share of options granted during the years ended December 31, 2011 and 2012 was $8.67 and $10.84, respectively.
	The amount of stock compensation expense related to consultant option grants, classified in selling, general and administrative expenses within the consolidated statements of operations, is marked to market at the end of each financial reporting period using the Black-Scholes option-pricing method and the period-end closing stock price, until such options vest. For the years ended December 31, 2011, 2012 and 2013, amounts reflected in the consolidated statements of operations related to consultant stock compensation expense, including the mark to market adjustment, was $1.1 million, $1.6 million and $2.9 million, respectively. These non-employee grants relate to a consulting agreement executed with the Company’s founding Chairman, Dr. Fred Eshelman. The terms of this consulting agreement provided for a grant of stock options to purchase shares of the Company’s common stock equal to 2.0% of the Company’s common stock outstanding immediately after the completion of the spin-off, and additional stock options for an additional 1.0% on or about the second anniversary of the spin-off.
	For the years ended December 31, 2011, 2012 and 2013, share based compensation expense related to stock options for the Company’s employees, directors and consultants under the Plan totaled $4.2 million, $5.5 million and $5.3 million, respectively, and is included in the accompanying consolidated financial statements. For the years ended December 31, 2011, 2012 and 2013, the Company received $0.6 million, $0.6 million and $3.6 million of cash from the exercise of stock options.
	A summary of option activity for the Plan as of December 31, 2011, 2012 and 2013, and changes during the years, is presented below:
			Shares			Weighted-Average			Weighted-Average			Aggregate
						Exercise Price			Remaining			Intrinsic
									Contractual Life (Years)			Value
	Outstanding at January 1, 2011			839		$	9.11
	Granted			742			13.87
	Exercised			(68	)		9.11
	Forfeited			(1	)		9.11
	Outstanding at December 31, 2011			1,512		$	11.45
	Exercisable at December 31, 2011			343		$	10.58
	Outstanding at January 1, 2012			1,512		$	11.45
	Granted			198			17.95
	Exercised			(66	)		9.11
	Forfeited			—			—
	Outstanding at December 31, 2012			1,644		$	12.33
	Exercisable at December 31, 2012			842		$	11.44
	Outstanding at January 1, 2013			1,644		$	12.33
	Granted			—			—
	Exercised			(307	)		11.77
	Forfeited			(2	)		17.8
	Outstanding at December 31, 2013			1,335		$	12.45			7.2		$	39,460
	Exercisable at December 31, 2013			1,120		$	11.96			7.1		$	33,646
	Vested or expected to vest at December 31, 2013			1,322		$	12.42			7.2		$	39,119
	The following table summarizes information about stock options outstanding for the Company as of December 31, 2013:
											Options Outstanding								Options Exercisable
		Range of									Number				Weighted-Average		Weighted-		Number		Weighted-
		Exercise Prices									Outstanding				Remaining		Average		Exercisable		Average
															Contractual Life (Years)		Exercise Price				Exercise Price
		$	9.11	—	13							536				6.5	$	9.11		536	$	9.11
		$	13.01	—	15							628				7.6		13.81		498		13.98
		$	15.01	—	17							2				8		16.71		1		16.71
		$	17.01	—	18.22							169				8.2		17.93		85		18.06
												1,335				7.2	$	12.45		1,120	$	11.96
	The aggregate fair value of options granted during the years ended December 31, 2011 and 2012 was $6.4 million and $2.1 million, respectively. The total intrinsic value (the amount by which the market value of the Company’s common stock exceeded the exercise price of the options on the date of exercise) of options exercised during the year ended December 31, 2011, 2012 and 2013 was $0.5 million, $0.8 million, and $9.0 million, respectively.
	A summary of the status of unvested options held by the Company’s employees, directors and consultants as of December 31, 2013, and changes during the year then ended, is presented below:
	Unvested Options		Shares			Weighted-
						Average
						Grant Date
						Fair Value
	Unvested at January 1, 2013			802		$	8.47
	Granted			—			—
	Vested			(585	)		8.09
	Forfeited			(1	)		10.87
	Unvested at December 31, 2013			216		$	9.47
	The total fair value of shares vested during the years ended December 31, 2011, 2012 and 2013 was $3.3 million, $5.0 million and $7.2 million, respectively. As of December 31, 2013, unrecognized compensation expense related to the unvested portion of the Company’s stock options granted to employees, directors and consultants was approximately $1.9 million, and will be recognized over a weighted-average period of 0.9 years. There was no associated income tax benefit recognized for the years ended December 31, 2011, 2012 or 2013 based on the Company’s valuation allowance that is recorded against its net deferred tax assets.
	The following table indicates the assumptions used in estimating fair value of each Plan option granted to employees and directors for the years ended December 31, 2011 and 2012. There were no employee or director option grants during the year ended December 31, 2013.
			2011									2012
	Expected term (years)		5.50				—	6					5.5	—	6
	Dividend yield (%)						—							—
	Risk-free interest rate (%)		1.10				—	2.18					0.84	—	1.15
	Expected volatility (%)		65.09				—	69.97					68.28	—	68.96
	The following table indicates the assumptions used in estimating fair value of each Plan option granted to consultants for the years ended December 31, 2011. There were no consultant option grants during the year ended December 31, 2012 and 2013.
			2011
	Expected term (years)			10
	Dividend yield (%)			—
Risk-free interest rate (%)			1.92
Expected volatility (%)			67.05
Expected option lives were based on the simplified method and volatilities used in fair valuation calculations are based on a benchmark of peer companies with similar expected lives. The Company does not currently intend to pay dividends on common stock; as a result, no dividend yield has been utilized in the fair valuation calculation. The risk-free interest rate is based on the rate at the date of grant for actively traded non-inflation-indexed issues adjusted to constant maturities with a term that approximates the expected term of the option.
Equity Compensation Plan – Restricted Stock
Beginning in 2013, the Company began issuing restricted stock to employees and directors of the Company. During the year ended December 31, 2013, the Company granted 136,779 restricted stock awards to employees and directors with a weighted-average price of $35.95. The restrictions on these awards lapse after a period of approximately one year in the case of annual director grants, or 50% on each of the first and second anniversary of grant in the case of employees and initial grants to new directors.
The fair value of the restricted stock was estimated using the fair value of the Company's common stock on the grant date and assumed no forfeiture rate based on the level of historical forfeitures associated with the Company’s stock options. The fair value of the Company's common stock on the grant date is equal to the most recent NASDAQ closing price of the Company's stock. The fair value of the restricted stock is being expensed on a straight-line basis over the period during which the restrictions lapse.
The aggregate fair value of restricted stock granted during the year ended December 31, 2013 was $4.9 million. For the year ended December 31, 2013, the Company recognized $1.6 million in share based compensation expense related to restricted stock. As of December 31, 2013, unrecognized compensation expense related to the unvested portion of the Company’s restricted stock granted to employees and directors was approximately $3.3 million, and will be recognized over a weighted-average period of 1.3 years. No shares of restricted stock vested during the year ended December 31, 2013.
A summary of restricted stock activity for the Plan as of December 31, 2013, and changes during the year, is presented below:
		Stock			Weighted-Average
					Price
Outstanding at January 1, 2013			—		$	—
Granted			137			35.95
Vested			—			—
Forfeited			—			—
Outstanding at December 31, 2013			137		$	35.95
Vested or expected to vest at December 31, 2013			137		$	35.95
A summary of the status of unvested restricted stock held by the Company’s employees and directors as of December 31, 2013, and changes during the year then ended, is presented below:
Unvested Restricted Stock		Stock			Weighted-
					Average
					Grant Date
					Fair Value
Unvested at January 1, 2013			—		$	—
Granted			137			35.95
Vested			—			—
Forfeited			—			—
Unvested at December 31, 2013			137		$	35.95

Note_9_Income_Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	9.    Income Taxes
	Taxes computed at the statutory U.S. federal income tax rate of 35% are reconciled to the provision for income taxes as follows:
		Year Ended December 31,
		2011			2012			2013
	Effective tax rate		0	%		0	%		(1.2	)%
	Statutory rate of 35%	$	(17,138	)	$	(14,998	)	$	(10,264	)
	State taxes, net of federal benefit		(284	)		(121	)		(13	)
	Permanent and other differences		371			377			(100	)
	Change in valuation allowance		17,065			13,934			10,496
	Adjustment to deferred state tax rate		—			822			229
	Provision for income taxes	$	14		$	14		$	348
	Components of the current deferred tax assets (liabilities) were as follows:
		December 31,
		2012			2013
	Accrued expenses	$	360		$	382
	Valuation allowance		(360	)		(382	)
	Total current deferred tax asset (liability)	$	—		$	—
	Components of the long-term deferred tax assets (liabilities) were as follows:
		December 31,
		2012			2013
	Depreciation and amortization	$	2,283		$	2,259
	Shared based compensation		2,567			4,261
	Future benefit of carry forward losses		42,688			51,470
	Valuation allowance		(47,758	)		(58,232	)
	Total long-term deferred tax asset (liability)	$	(220	)	$	(242	)
	For the years ended December 31, 2011, 2012 and 2013, the Company recorded an insignificant amount of income tax expense related to the adjustment of a deferred tax liability associated with historical goodwill, which is amortized and deductible for tax purposes, but is an indefinite-lived intangible asset for financial reporting purposes. The tax effect of the tax amortization of this item is reflected in the statements of operations for the years ended December 31, 2011, 2012 and 2013. As the associated deferred tax liability associated with historical goodwill relates to an indefinite-lived intangible, the Company does not consider this item in computing the valuation allowance related to the Company's net deferred tax assets. As of December 31, 2012 and 2013, the deferred tax liability associated with this intangible asset, reflected in other long-term liabilities within the consolidated balance sheets, was approximately $0.2 million, respectively. In addition, for the year ended December 31, 2013, the Company recognized $0.3 million of state income tax expense related to one of its consolidated subsidiaries that has rights to Priligy. Due to the historical losses from the Company's operations, a full valuation allowance on deferred tax assets has been recorded.
	The Company has determined that any uncertain tax positions for the tax years open for examination would have no material impact on the consolidated financial statements of the Company. The Company has federal operating loss carry forwards of approximately $149.2 million that will begin to expire in 2030. Of the total federal carry forwards, approximately $6.7 million relates to stock compensation tax deductions that will be tax-effected and the related benefit reflected in additional paid-in capital, when realized. The Company also has state operating loss carry forwards of approximately $43.1 million that will begin to expire in 2030. In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards might be limited.

Note_10_Employee_Savings_Plan

Note 10 - Employee Savings Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	10.    Employee Savings Plan
	Company employees are eligible to participate in the Furiex 401(k) Retirement Savings Plan. The Company’s plan matches 100% of an employee’s savings up to 4% of the employee’s deferral, and those contributions vest immediately. The Company’s contributions to the plan, net of forfeitures, were $0.14 million, $0.15 million and $0.15 million for the years ended December 31, 2011, 2012 and 2013, respectively.

Note_11_Commitments_and_Contin

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	11.    Commitments and Contingencies
	The Company is involved in compound development and commercialization collaborations. As of December 31, 2013, the Company's four main collaborations were with Janssen Pharmaceutica, NV, or Janssen (an affiliate of Johnson & Johnson), related to JNJ-Q2 and eluxadoline (historically referred to by the Company as MuDelta) and the product Priligy (dapoxetine), and Alza Corporation, or Alza, related to the product Priligy. The Company also has out-license agreements with Berlin-Chemie AG (Menarini Group), or Menarini, related to the product Priligy and Takeda Pharmaceuticals Company Limited, or Takeda, related to the trelagliptin compound, Nesina (alogliptin), and alogliptin-related combination products. The Company has no on-going commitments under the out-license agreements.
	As of December 31, 2013, the Company had two collaborations that involve potential future expenditures. The first is its collaboration with Alza and Janssen for Priligy.
	On May 14, 2012, the Company and its wholly-owned subsidiary Genupro, Inc. (“Genupro”) entered into a license and asset transfer agreement with Alza and Janssen, whereby Alza and Janssen transferred to the Company worldwide rights for Priligy. To facilitate a uniform transition, Janssen agreed to continue to manufacture and manage certain clinical and regulatory activities with respect to Priligy for a pre-defined period after the closing date of the agreement. This transaction became effective on July 30, 2012. Under the terms of this transaction, the Company was obligated to pay Janssen for transition services provided to the Company in the amount of $15.0 million, with $7.5 million paid within 45 days of closing, and $3.75 million due within 10 business days of the beginning of each of the following two calendar quarters. As of December 31, 2013, no amounts remained due to Janssen for these transition services. In addition, the Company is obligated to pay Janssen up to $19.0 million in potential on-going clinical study costs and up to $1.0 million for reasonable out-of-pocket expenses over the transition period. The Company must also pay Janssen fees related to Priligy sales and distribution activities that Janssen will perform for the Company during the transition period pursuant to a sales services agreement. Priligy will continue to be made available to patients under the sales service agreement until the marketing authorizations are transferred, at which time commercialization of the product will transition to the Company or its licensee. The term of the license and asset transfer agreement will expire on the latest of the completion of the transition of the product rights to the Company, the expiration of its last payment obligation to Janssen, or the expiration of the last-to-expire ancillary agreement.
	The Company's collaboration with Alza and Janssen for Priligy, as described above, is associated with an out-license agreement under which the Company has received, and is eligible to receive, additional payments. On May 14, 2012, Genupro entered into a license agreement with Menarini by which the Company licensed to Menarini exclusive rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. This transaction became effective on July 30, 2012. The Company retained full development and commercialization rights in the U.S., Japan and Canada. Menarini will assume responsibility for commercialization activities in the licensed territories and will fund the on-going clinical studies being performed by Janssen. Under the license agreement with Menarini, the Company received a $15.0 million upfront payment and $10.0 million of regulatory milestone payments during the third quarter of 2012. During the third quarter of 2012, the Company recognized milestone revenue of $10.0 million related to this agreement for regulatory submissions. The $15.0 million upfront payment received during the third quarter of 2012 was not recorded as milestone revenue based on agent and principal considerations, as discussed below. During 2013, the Company recognized milestone revenue of $10.0 million related to this agreement for the commercial launch of Priligy in France and the United Kingdom. In addition, under this agreement, the Company is eligible to receive up to $19.0 million in pass-through payments to fund potential on-going clinical study costs being performed by Janssen and up to $40.0 million in sales-based milestones, plus tiered royalties ranging from the mid-teens to mid-twenties in percentage terms. The term of the license agreement (and the period during which Menarini must pay the Company royalties in a particular country for a particular product) will end, on a country-by-country basis, upon the latest of (i) the expiration of a valid relevant patent claim in that country, (ii) the expiration of marketing and data exclusivity in that country, or (iii) a third party’s market entry of an approved product in that country containing dapoxetine for use, on an as needed basis, for premature ejaculation.
	In connection with the license and asset transfer agreement with Alza and Janssen, and the license agreement with Menarini, the Company assessed the indicators associated with agent and principal considerations for each transaction. Based on the terms of the underlying agreements, the nature of the related cash payments and receipts (regarding the $15.0 million up-front and transition service payments, the up to $19.0 million to fund potential on-going clinical study costs and the fees related to Priligy sales and distribution activities performed by Janssen), and the determination that the Company is not the primary obligor for the underlying activities that are associated with these payments, the Company has recorded these amounts on a net basis within the consolidated statements of operations. For the quarter ended December 31, 2013, the Company owed amounts to Janssen, and correspondingly received equal payments from Menarini, totaling $0.2 million related to on-going clinical studies for Priligy. The Company has also considered the contractual right-of-offset related to these payments, for which the Company is effectively an intermediary, and has recorded these amounts on a gross basis within the consolidated balance sheets. As of December 31, 2013, approximately $0.2 million is reflected in accrued expenses related to the on-going Priligy clinical study costs being performed by Janssen.
	The Company originally acquired patents for Priligy from Eli Lilly and Company, or Lilly, and is obligated to pay Lilly a royalty of 5% on annual sales in excess of $800.0 million. In addition, under the terms of the license agreement with Menarini, Menarini will pay the portion of the royalties owed to Lilly in each country where Menarini is licensed to sell Priligy, where Lilly is eligible for payments, and where the Company is no longer eligible for payments from Menarini. The term of the license agreement with Lilly (and the period during which the Company or Menarini must pay Lilly royalties in a particular country) will end, on a country-by-country basis, upon the later of (i) the last to expire valid patent claim licensed to Lilly in that country, (ii) the expiration of data exclusivity in that country, or (iii) the tenth anniversary of the first date of sale of Priligy in that country.
	The second collaboration involving future expenditures is associated with the two compounds in-licensed from Janssen: JNJ-Q2 and eluxadoline. The Company has full exclusive license rights to develop and commercialize JNJ-Q2 and eluxadoline under its existing development and license agreements with Janssen.
	The Company plans to continue evaluating other partnering and funding opportunities for both the JNJ-Q2 and eluxadoline compounds. The Company may be obligated to pay Janssen up to $50.0 million in regulatory milestone payments for the JNJ-Q2 compound, up to $45.0 million in regulatory milestone payments for the eluxadoline compound, and, if approved for marketing, for both the JNJ-Q2 and eluxadoline compounds, individually, up to $75.0 million in sales-based milestone payments and sales-based royalties increasing from the mid- to upper-single digit percentages as sales volume increases. Royalties would be paid for a period of ten years after the first commercial sale or, if later, the expiration of the last valid patent claim or the expiration of patent exclusivity.
	The Company currently maintains insurance for risks associated with the operation of its business. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability and product liability. The Company might be a party to various claims and legal proceedings in the normal course of business. As of December 31, 2013, there are no outstanding claims or legal proceedings that management believes will have a material effect upon the Company’s financial condition, results of operations or cash flows.

Note_12_Fair_Value_Measurement

Note 12 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	12.    Fair Value Measurements
	Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying such assumptions, a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is applied as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. There were no transfers between such levels for the ended December 31, 2012 or 2013.
	The following table provides the assets and liabilities carried at fair value measured on a recurring basis at December 31, 2012 and December 31, 2013:
		31-Dec-12
				Fair Value Measurements Using
		Total		(Level 1)		(Level 2)		(Level 3)
		Carrying
		Value
	Assets:
	Cash equivalents - money market mutual funds	$	23,727	$	23,727	$	—	$	—
	Investments - money market mutual funds		7,500		7,500		—		—
	Liabilities:	$	—	$	—	$	—	$	—
		31-Dec-13
				Fair Value Measurements Using
		Total		(Level 1)		(Level 2)		(Level 3)
		Carrying
		Value
	Assets:
	Cash equivalents - money market mutual funds	$	16,563	$	16,563	$	—	$	—
	Liabilities:	$	—	$	—	$	—	$	—
	The Company's money market mutual funds are valued using readily available market prices.
	The carrying amounts reflected in the Company's consolidated balance sheets for cash, accounts receivable, prepaid expenses, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. The carrying value of long-term and related party debt at December 31, 2013 approximates its fair value as there have been no significant changes in interest rates or the creditworthiness of the Company since the debt was incurred in September 2013.

Note_13_Segment_Information

Note 13 - Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	13.    Segment Information
	The Company’s business consists solely of compound development and collaboration activities. Accordingly, the Company operates in one reportable business segment.

Note_14_Quarterly_Financial_Da

Note 14 - Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	14.    Quarterly Financial Data (unaudited)
			First			Second			Third			Fourth			Total
	2012
	Total revenue (a)		$	2,645		$	13,075		$	15,577		$	9,211		$	40,508
	Operating loss			(9,477	)		(20,489	)		(2,452	)		(7,926	)		(40,344	)
	Net loss			(9,758	)		(20,769	)		(3,286	)		(9,052	)		(42,865	)
	Net income (loss) per basic share			-			-			-			-			-
	Net income (loss) per diluted share			-			-			-			-			-
	Net loss per basic and diluted share		$	(0.98	)	$	(2.09	)	$	(0.33	)	$	(0.90	)	$	(4.29	)
	2013
	Total revenue (b)		$	39,325		$	2,990		$	15,550		$	13,134		$	70,999
	Operating income (loss)			10,067			(22,315	)		(7,550	)		(4,638	)		(24,438	)
	Net income (loss)			8,966			(23,453	)		(8,683	)		(6,500	)		(29,673	)
	Net income (loss) per basic share		$	0.89		$	(2.32	)	$	(0.85	)	$	(0.63	)	$	(2.92	)
	Net income (loss) per diluted share		$	0.82		$	(2.32	)	$	(0.85	)	$	(0.63	)	$	(2.92	)
	Net loss per basic and diluted share			-			-			-			-			-
	(a)	The second quarter of 2012 includes a $10.0 million regulatory milestone related to the acceptance of the submission of a Marketing Authorization Application by the European Medicines Agency for alogliptin in May 2012. The third quarter of 2012 includes a $10.0 million launch-based milestone related to the Priligy license agreement with Menarini.
	(b)	The first quarter of 2013 includes a $25.0 million regulatory milestone from Takeda with respect to the FDA approval of three new alogliptin-related products in January 2013 and a $5.0 million milestone from Menarini upon the launch of Priligy in France in March 2013. The third quarter of 2013 includes a $10.0 million milestone from Takeda upon the European Marketing Authorization of alogliptin and related products in September 2013. The fourth quarter of 2013 includes a $5.0 million milestone from Menarini upon the launch of Priligy in the United Kingdom in October 2013.
	Total net loss per basic and diluted share for 2012 differs from the sum of quarterly amounts due to rounding. Total operating income (loss), net income (loss) and net income (loss) per basic and diluted share for 2013 differs from the sum of quarterly amounts due to rounding.

Note_15_Subsequent_Event

Note 15 - Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	15.    Subsequent Events
	On February 4, 2014 the Company announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome met both the U.S. Food and Drug Administration and the European Medicines Agency formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Organization and Business Description
	Furiex Pharmaceuticals, Inc., a Delaware corporation (“Furiex” or the “Company”), is a drug development company that continues the compound partnering business started by Pharmaceutical Product Development, Inc. (“PPD”) in 1998. On June 14, 2010, PPD effected the spin-off of Furiex through a tax-free, pro-rata dividend distribution of all of the shares of the Company to PPD shareholders. The goal of the Company is to in-license compounds from, or form strategic alliances with, pharmaceutical and biotechnology companies to share the risks and rewards of developing therapeutics. The Company's operations are headquartered in Morrisville, North Carolina.
	The Company has incurred losses and negative cash flows from operations since the spin-off and expects to continue to incur operating losses until revenues from all sources reach a level sufficient to support its on-going operations. The Company’s liquidity will largely be determined by its ability to raise capital from debt, equity, or other forms of financing, by the success of its products already being commercialized by collaborators, by key development and regulatory events that might impact its ability to out-license its development compounds, by its ability to enter into new collaborations and their terms, and by expenses associated with operations including research and development and potential commercialization efforts.
	The Company’s liquidity over the next 12 months could be materially affected by, among other things: its ability to raise additional funds through debt, equity or other financing alternatives; costs related to its development and potential commercialization efforts; regulatory approval and commercialization of its compound candidates, which could affect selling, general and administrative expenses and milestone and royalty receipts; changes in regulatory compliance requirements; reliance on existing collaborators and potential need to enter into additional collaborative arrangements; and other factors. Depending upon the success and timing of potential new collaborations or potential commercialization efforts and receipt of various milestone payments and royalties, it might be necessary to do one or more of the following in the next 12 months: (a) raise additional capital through equity or debt financings or from other sources; (b) reduce spending on research and development and/or commercialization of eluxadoline; or (c) restructure the Company's operations. The Company currently receives on-going revenue from royalties on sales of Nesina® and related combination products, as well as Priligy®.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The Company prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, and they include the accounts of Furiex Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates in Preparation of the Financial Statements
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings Per Share
	The Company calculates net income (loss) per basic share by dividing net income (loss) by the weighted-average number of shares outstanding during the reporting period. The Company calculates net income (loss) per diluted share by dividing net income (loss) by the weighted-average number of shares outstanding during the reporting period plus the effects of any dilutive common stock-based awards. All potentially dilutive securities relate to stock options and restricted stock awards issued as part of the Company's share-based compensation plan. The calculation of net loss per diluted share for the years ended December 31, 2011, 2012 and 2013 is the same as net loss per basic share because the inclusion of any potentially dilutive securities would be anti-dilutive. Potentially dilutive securities totaling approximately 1,511,000, 1,644,000 and 1,472,000 for the years ended December 31, 2011, 2012 and 2013, respectively, were excluded from the calculation of diluted loss per share because of their anti-dilutive effect.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive Income (Loss)
	There are no items of comprehensive loss other than net loss for any periods presented.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company generates revenue in the form of upfront payments, development and regulatory milestone payments, royalties, and launch-based and sales-based milestone payments in connection with the out-license or sale of products. The receipt of future milestone payments and royalties depends on the success of the Company's compound development and the Company's collaborators' success in developing and commercializing compounds. Upfront payments are generally paid within a short period of time following the execution of an out-license or collaboration agreement. Development and regulatory milestone payments are typically one-time payments to the Company triggered by the collaborator's achievement of specified development and regulatory events such as the commencement of Phase III trials or regulatory submission approval. Royalties are payments received by the Company based on net product sales of a collaborator. Launch-based milestone payments are one-time payments to the Company triggered when a collaborator first introduces for sale an out-licensed product in a new geographical region. Sales-based milestone payments are typically one-time payments to the Company triggered when aggregate net sales of product by a collaborator for a specified period (for example, an annual period) reach an agreed upon threshold amount. The Company recognizes upfront payments, development and regulatory milestone payments, royalty payments, and launch-based and sales-based milestone payments from its collaborators when the event that triggers the obligation of payment has occurred, there is no further obligation on the Company's part in connection with the payment and collection is reasonably assured.
	The Company assesses each collaboration agreement it enters into for potential indicators associated with agent and principal considerations for each related cash payment and receipt. Based on the terms of the underlying agreement and the determination of which party to the transaction is the primary obligor, the Company records the underlying activities that are associated with contractual payments within the consolidated statements of operations and consolidated balance sheets on a net or gross basis, accordingly.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	The Company's collaborators, which are its current sources of revenue, are primarily pharmaceutical companies. A concentration of credit risk with respect to revenue exists due to the small number of collaborators. Three collaborators accounted for all of the Company's revenue for the years ended December 31, 2011, 2012 and 2013. The first collaborator accounted for $3.6 million, $28.1 million and $58.7 million of total revenue for the years ended December 31, 2011, 2012 and 2013, respectively. The second collaborator accounted for $0.8 million, $2.4 million and $0.6 million of total revenue for the years ended December 31, 2011, 2012 and 2013, respectively. The third collaborator accounted for $10.0 million and $11.7 million of total revenue for the years ended December 31, 2012 and 2013, respectively. The Company had no revenue from the third collaborator for the year ended December 31, 2011.
	Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and accounts receivable. All of the Company's cash is held in deposit accounts at a major financial institution, which management assesses to be of high credit quality. The Company’s money market fund investments (categorized as cash and cash equivalents) are with what the Company believes are high quality issuers. The Company has not experienced any losses in such accounts.
	The December 31, 2012 and 2013 balance of accounts receivable relates to royalty receivables related to Nesina and its combination products and Priligy based on net product sales and activities by the Company's collaborators and, as described in Note 11, amounts due from a collaborator to fund on-going clinical study costs associated with Priligy. The first, second and third collaborator accounted for $8.0 million, $2.0 million and $1.7 million, respectively, of the accounts receivable balance as of December 31, 2012. The first, second and third collaborator accounted for $7.5 million, $0.1 million and $0.6 million, respectively, of the accounts receivable balance as of December 31, 2013.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenses
	Research and development costs consist primarily of costs associated with pre-clinical studies, non-clinical studies and the clinical trials of the Company's compounds, development materials, labor and related benefit charges associated with personnel performing research and development work, supplies associated with this work and consulting services. Research and development costs include clinical research services, pre-clinical testing, non-clinical testing and clinical drug manufacturing provided by third parties, the direct cost of the Company's personnel managing the programs and upfront and milestone payments to the Company's collaborators. The Company accrues certain costs related to clinical studies, including investigative site payments, based on estimates of the services performed and efforts expended. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual accordingly. The Company charges research and development costs to operations as incurred and discloses them in the consolidated statements of operations.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the year, plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial reporting and tax basis of the Company's assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when enacted.
	Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment, including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. Due to the historical losses from the Company's operations, a full valuation allowance on deferred tax assets has been recorded.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Compensation
	The Company recognizes compensation expense using a fair-value based method related to stock options, restricted stock awards and other share-based compensation. The expense is measured based on the grant date fair value of the awards that are expected to vest and is recorded over the applicable requisite service period. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	'
	Goodwill
	The Company records as goodwill the excess of the purchase price of a business acquired over the fair value of net tangible assets and identifiable intangible assets at the date of the acquisition. The Company evaluates goodwill for impairment on an annual basis each October 1 or more frequently if events or changes in circumstances indicate that goodwill might be impaired. Any impairment could have a material adverse effect on the Company's financial condition and results of operations.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash, Cash Equivalents, and Investments
	Cash and cash equivalents consist of unrestricted cash accounts and money market funds that hold short-term U.S. Treasury securities that are not subject to withdrawal restrictions or penalties. The Company considers all cash on deposit and money market accounts with original maturities of three months or less at time of purchase to be cash and cash equivalents.
	Investments consisted of restricted cash accounts and money market funds that held short-term U.S. Treasury securities that were subject to contractual withdrawal restrictions and penalties. Under the Amended and Restated Loan and Security Agreement with Midcap Funding III, LLC, Midcap Funding RE Holdings, LLC and Silicon Valley Bank, the Company was required to maintain a minimum cash balance with Silicon Valley Bank. However, on September 30, 2013, the Company and its subsidiaries entered into a Second Amended and Restated Loan and Security Agreement with Midcap Funding III, LLC, Midcap Funding V, LLC and Silicon Valley Bank. Under the Second Amended and Restated Loan and Security Agreement, the Company is still required to maintain its primary deposit and investment accounts with Silicon Valley Bank, consisting of at least 50% of the Company's total cash and cash equivalents balance. However, the Second Amended and Restated Loan and Security Agreement does not require the Company to maintain a minimum cash balance.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	The Company records property and equipment at cost less accumulated depreciation. The Company records depreciation using the straight-line method, based on the following estimated useful lives:
		Years
	Furniture and equipment		5	–	10
	Computer equipment and software		2	–	5
Lease, Policy [Policy Text Block]	'
	Operating Leases
	The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The Company begins amortization on the date of initial possession, which is generally when the Company enters the space and begins to make improvements in preparation for its intended use. The Company accounts for the difference between rent expense and rent paid as deferred rent. The Company records a deferred rent liability at the inception of the lease term and amortizes the deferred rent over the term of the lease as a reduction to rent expense.

Note_1_Summary_of_Operations_a1

Note 1 - Summary of Operations and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Estimated Useful Lives [Table Text Block]	'
		Years
	Furniture and equipment		5	–	10
	Computer equipment and software		2	–	5

Note_2_Accounts_Receivable_Tab

Note 2 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
		December 31,
		2012		2013
	Royalties	$	10,045	$	8,147
	Priligy on-going clinical study costs (Note 11) and other		1,700		31
		$	11,745	$	8,178

Note_3_Property_and_Equipment_

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		December 31,
		2012			2013
	Furniture and equipment	$	98		$	98
	Computer equipment and software		245			271
	Total property and equipment		343			369
	Less accumulated depreciation		(225	)		(282	)
	Total property and equipment, net	$	118		$	87

Note_5_Accrued_Expenses_Tables

Note 5 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		December 31,
		2012		2013
	Salaries, wages, benefits and related costs	$	1,181	$	1,315
	Research and development costs		3,143		3,057
	Professional fees		101		89
	Interest		344		634
	Janssen transition service payments (Note 11)		3,750		—
	Priligy on-going clinical study costs (Note 11)		1,700		207
	Other		11		—
		$	10,230	$	5,302

Note_6_LongTerm_Debt_Tables

Note 6 - Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Long Term Debt Outstanding [Table Text Block]	'
		December 31,
		2012			2013
	Total debt, third party	$	40,000		$	42,000
	Less current portion of long-term debt, third party		(5,405	)		(10,080	)
	Long-term debt, third party, net	$	34,595		$	31,920
		December 31,
		2012			2013
	Total debt, related party	$	—		$	15,000
	Less current portion of long-term debt, related party		—			(500	)
	Long-term debt, related party, net	$	—		$	14,500
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	2014	$	10,080
	2015		16,800
	2016		15,120
	2017		—
		$	42,000
	2014	$	500
	2015		2,000
	2016		2,000
	2017		10,500
		$	15,000

Note_8_ShareBased_Compensation1

Note 8 - Share-Based Compensation (Tables) (Furiex Plan [Member])	12 Months Ended
	Dec. 31, 2013
Note 8 - Share-Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Shares			Weighted-Average			Weighted-Average			Aggregate
						Exercise Price			Remaining			Intrinsic
									Contractual Life (Years)			Value
	Outstanding at January 1, 2011			839		$	9.11
	Granted			742			13.87
	Exercised			(68	)		9.11
	Forfeited			(1	)		9.11
	Outstanding at December 31, 2011			1,512		$	11.45
	Exercisable at December 31, 2011			343		$	10.58
	Outstanding at January 1, 2012			1,512		$	11.45
	Granted			198			17.95
	Exercised			(66	)		9.11
	Forfeited			—			—
	Outstanding at December 31, 2012			1,644		$	12.33
	Exercisable at December 31, 2012			842		$	11.44
	Outstanding at January 1, 2013			1,644		$	12.33
	Granted			—			—
	Exercised			(307	)		11.77
	Forfeited			(2	)		17.8
	Outstanding at December 31, 2013			1,335		$	12.45			7.2		$	39,460
	Exercisable at December 31, 2013			1,120		$	11.96			7.1		$	33,646
	Vested or expected to vest at December 31, 2013			1,322		$	12.42			7.2		$	39,119
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
											Options Outstanding								Options Exercisable
		Range of									Number				Weighted-Average		Weighted-		Number		Weighted-
		Exercise Prices									Outstanding				Remaining		Average		Exercisable		Average
															Contractual Life (Years)		Exercise Price				Exercise Price
		$	9.11	—	13							536				6.5	$	9.11		536	$	9.11
		$	13.01	—	15							628				7.6		13.81		498		13.98
		$	15.01	—	17							2				8		16.71		1		16.71
		$	17.01	—	18.22							169				8.2		17.93		85		18.06
												1,335				7.2	$	12.45		1,120	$	11.96
Schedule of Share Based Compensation Unvested Options [Table Text Block]	'
	Unvested Options		Shares			Weighted-
						Average
						Grant Date
						Fair Value
	Unvested at January 1, 2013			802		$	8.47
	Granted			—			—
	Vested			(585	)		8.09
	Forfeited			(1	)		10.87
	Unvested at December 31, 2013			216		$	9.47
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
			Stock			Weighted-Average
						Price
	Outstanding at January 1, 2013			—		$	—
	Granted			137			35.95
	Vested			—			—
	Forfeited			—			—
	Outstanding at December 31, 2013			137		$	35.95
	Vested or expected to vest at December 31, 2013			137		$	35.95
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	Unvested Restricted Stock		Stock			Weighted-
						Average
						Grant Date
						Fair Value
	Unvested at January 1, 2013			—		$	—
	Granted			137			35.95
	Vested			—			—
	Forfeited			—			—
	Unvested at December 31, 2013			137		$	35.95
Options Granted to Employees and Directors [Member]	'
Note 8 - Share-Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			2011									2012
	Expected term (years)		5.50				—	6					5.5	—	6
	Dividend yield (%)						—							—
	Risk-free interest rate (%)		1.10				—	2.18					0.84	—	1.15
	Expected volatility (%)		65.09				—	69.97					68.28	—	68.96
Options Granted to Consultants [Member]	'
Note 8 - Share-Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			2011
	Expected term (years)			10
	Dividend yield (%)			—
	Risk-free interest rate (%)			1.92
	Expected volatility (%)			67.05

Note_9_Income_Taxes_Tables

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		Year Ended December 31,
		2011			2012			2013
	Effective tax rate		0	%		0	%		(1.2	)%
	Statutory rate of 35%	$	(17,138	)	$	(14,998	)	$	(10,264	)
	State taxes, net of federal benefit		(284	)		(121	)		(13	)
	Permanent and other differences		371			377			(100	)
	Change in valuation allowance		17,065			13,934			10,496
	Adjustment to deferred state tax rate		—			822			229
	Provision for income taxes	$	14		$	14		$	348
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		December 31,
		2012			2013
	Accrued expenses	$	360		$	382
	Valuation allowance		(360	)		(382	)
	Total current deferred tax asset (liability)	$	—		$	—
		December 31,
		2012			2013
	Depreciation and amortization	$	2,283		$	2,259
	Shared based compensation		2,567			4,261
	Future benefit of carry forward losses		42,688			51,470
	Valuation allowance		(47,758	)		(58,232	)
	Total long-term deferred tax asset (liability)	$	(220	)	$	(242	)

Note_12_Fair_Value_Measurement1

Note 12 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		31-Dec-12
				Fair Value Measurements Using
		Total		(Level 1)		(Level 2)		(Level 3)
		Carrying
		Value
	Assets:
	Cash equivalents - money market mutual funds	$	23,727	$	23,727	$	—	$	—
	Investments - money market mutual funds		7,500		7,500		—		—
	Liabilities:	$	—	$	—	$	—	$	—
		31-Dec-13
				Fair Value Measurements Using
		Total		(Level 1)		(Level 2)		(Level 3)
		Carrying
		Value
	Assets:
	Cash equivalents - money market mutual funds	$	16,563	$	16,563	$	—	$	—
	Liabilities:	$	—	$	—	$	—	$	—

Note_14_Quarterly_Financial_Da1

Note 14 - Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
		First			Second			Third			Fourth			Total
	2012
	Total revenue (a)	$	2,645		$	13,075		$	15,577		$	9,211		$	40,508
	Operating loss		(9,477	)		(20,489	)		(2,452	)		(7,926	)		(40,344	)
	Net loss		(9,758	)		(20,769	)		(3,286	)		(9,052	)		(42,865	)
	Net income (loss) per basic share		-			-			-			-			-
	Net income (loss) per diluted share		-			-			-			-			-
	Net loss per basic and diluted share	$	(0.98	)	$	(2.09	)	$	(0.33	)	$	(0.90	)	$	(4.29	)
	2013
	Total revenue (b)	$	39,325		$	2,990		$	15,550		$	13,134		$	70,999
	Operating income (loss)		10,067			(22,315	)		(7,550	)		(4,638	)		(24,438	)
	Net income (loss)		8,966			(23,453	)		(8,683	)		(6,500	)		(29,673	)
	Net income (loss) per basic share	$	0.89		$	(2.32	)	$	(0.85	)	$	(0.63	)	$	(2.92	)
	Net income (loss) per diluted share	$	0.82		$	(2.32	)	$	(0.85	)	$	(0.63	)	$	(2.92	)
	Net loss per basic and diluted share		-			-			-			-			-

Note_1_Summary_of_Operations_a2

Note 1 - Summary of Operations and Significant Accounting Policies (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Note 1 - Summary of Operations and Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)

'

'

'

'

'

'

'

'

1,472,000

1,644,000

1,511,000

Number Of Collaborators Accounting For Revenue

'

'

'

'

'

'

'

'

3

3

3

Revenues

$13,134,000

[1]

$15,550,000

[1]

$2,990,000

[1]

$39,325,000

[1]

$9,211,000

[2]

$15,577,000

[2]

$13,075,000

[2]

$2,645,000

[2]

$70,999,000

[1]

$40,508,000

[2]

$4,490,000

Accounts Receivable, Net, Current

8,178,000

'

'

'

11,745,000

'

'

'

8,178,000

11,745,000

'

First Collaborator [Member]

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Summary of Operations and Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

58,700,000

28,100,000

3,600,000

Accounts Receivable, Net, Current

7,500,000

'

'

'

8,000,000

'

'

'

7,500,000

8,000,000

'

Second Collaborator [Member]

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Summary of Operations and Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

600,000

2,400,000

800,000

Accounts Receivable, Net, Current

100,000

'

'

'

2,000,000

'

'

'

100,000

2,000,000

'

Third Collaborator [Member]

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Summary of Operations and Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

11,700,000

10,000,000

0

Accounts Receivable, Net, Current

$600,000

'

'

'

$1,700,000

'

'

'

$600,000

$1,700,000

'

Through Maturity Date [Member]

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Summary of Operations and Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Required Deposit Percentage

50.00%

'

'

'

'

'

'

'

50.00%

'

'

[1]

The first quarter of 2013 includes a $25.0 million regulatory milestone from Takeda with respect to the FDA approval of three new alogliptin-related products in January 2013 and a $5.0 million milestone from Menarini upon the launch of Priligy in France in March 2013. The third quarter of 2013 includes a $10.0 million milestone from Takeda upon the European Marketing Authorization of alogliptin and related products in September 2013. The fourth quarter of 2013 includes a $5.0 million milestone from Menarini upon the launch of Priligy in the United Kingdom in October 2013.

[2]

The second quarter of 2012 includes a $10.0 million regulatory milestone related to the acceptance of the submission of a Marketing Authorization Application by the European Medicines Agency for alogliptin in May 2012. The third quarter of 2012 includes a $10.0 million launch-based milestone related to the Priligy license agreement with Menarini.

Note_1_Summary_of_Operations_a3

Note 1 - Summary of Operations and Significant Accounting Policies (Details) - Estimated Useful Lives	12 Months Ended
	Dec. 31, 2013
Furniture and Fixtures [Member] | Minimum [Member]	'
Note 1 - Summary of Operations and Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Property Plant and Equipment Useful Lives	'5 years
Furniture and Fixtures [Member] | Maximum [Member]	'
Note 1 - Summary of Operations and Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Property Plant and Equipment Useful Lives	'10 years
Computer Equipment [Member] | Minimum [Member]	'
Note 1 - Summary of Operations and Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Property Plant and Equipment Useful Lives	'2 years
Computer Equipment [Member] | Maximum [Member]	'
Note 1 - Summary of Operations and Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Property Plant and Equipment Useful Lives	'5 years

Note_2_Accounts_Receivable_Det

Note 2 - Accounts Receivable (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]	'	'
Provision for Doubtful Accounts	$0	$0

Note_2_Accounts_Receivable_Det1

Note 2 - Accounts Receivable (Details) - Accounts Receivable (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts Receivable	$8,178	$11,745
Royalty [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts Receivable	8,147	10,045
Priligy Clinical Study Costs [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts Receivable	$31	$1,700

Note_3_Property_and_Equipment_1

Note 3 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Capital Expenditures Incurred but Not yet Paid	$0	$0

Note_3_Property_and_Equipment_2

Note 3 - Property and Equipment (Details) - Property and Equipment, Stated at Cost (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property and Equipment, Stated at Cost [Abstract]	'	'
Furniture and equipment	$98	$98
Computer equipment and software	271	245
Total property and equipment	369	343
Less accumulated depreciation	-282	-225
Total property and equipment, net	$87	$118

Note_4_Goodwill_Details

Note 4 - Goodwill (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block Supplement [Abstract]	'	'
Goodwill, Period Increase (Decrease)	$0	$0
Goodwill, Impaired, Accumulated Impairment Loss	$0	$0

Note_5_Accrued_Expenses_Detail

Note 5 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]	'	'
Salaries, wages, benefits and related costs	$1,315	$1,181
Research and development costs	3,057	3,143
Professional fees	89	101
Interest	634	344
Janssen transition service payments (Note 11)	'	3,750
Priligy on-going clinical study costs (Note 11)	207	1,700
Other	'	11
	$5,302	$10,230

Note_6_LongTerm_Debt_Details

Note 6 - Long-Term Debt (Details) (USD $)

12 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Aug. 18, 2011

Aug. 02, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

Board of Directors Chairman [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

Silicon Valley Bank [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Eshelman Loan [Member]

Eshelman Loan [Member]

Eshelman Loan [Member]

Eshelman Loan [Member]

Initial Agreement [Member]

First Amended Agreement [Member]

Second Amended Agreement [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

MidCap Funding III LLC And Sillicon Valley Bank [Member]

Note 6 - Long-Term Debt (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

$10,000,000

'

$42,000,000

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

9.00%

'

'

10.25%

'

10.00%

'

'

'

'

'

'

Debt Instrument Increase Additional Borrowings 1

'

'

'

'

'

'

'

'

30,000,000

'

'

'

'

'

'

'

Principal Payments of Alogliptin Royalties

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

50.00%

Monetary Principal Payments of Alogliptin Royalties

'

'

'

'

'

'

'

'

'

'

'

'

'

1,260,000

'

4,200,000

Required Deposit Percentage

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

Final Payment Fee

'

'

'

'

'

'

'

'

'

'

3.50%

'

'

'

'

'

Prepayment Penalty Percentage

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

3.50%

'

Gross Final Payment Fee

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Amount of Deferred Financing Costs

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Event Of Default Interest Rate On Long Term Debt

'

'

'

'

'Under the Eshelman Loan, the Company and its subsidiaries are subject to affirmative covenants substantially consistent to the Second Amended Agreement loan. The Eshelman Loan also has events of default that are substantially consistent to the Second Amended Agreement loan, except for upon occurrence of any event of default, the Company's obligations under the Eshelman Loan will bear interest at a rate equal to the lesser of (a) 3% above the rate of interest applicable to such obligations immediately prior to the occurrence of the event of default or (b) the maximum rate allowable under law. As of December 31, 2013, the Company was in compliance with its obligations under the Eshelman Loan.

'

'

'

'

'

'Upon the occurrence of any event of default, the Company's obligations under the Second Amended Agreement will bear interest at a rate equal to the lesser of (a) 4% above the rate of interest applicable to such obligations immediately prior to the occurrence of the event of default or (b) the maximum rate allowable under law.

'

'

'

'

'

Related Party Stockholder Percentage

'

'

'

'

'

27.20%

'

'

'

'

'

'

'

'

'

'

Due to Related Parties, Noncurrent

14,500,000

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

'

166,667

'

'

'

'

'

'

'

'

'

'

'

'

Unrestricted Cash On Hand After Principal Payment

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

Interest Expense

$4,980,000

$2,508,000

$413,000

'

$300,000

'

'

'

'

'

'

'

'

'

'

'

Note_6_LongTerm_Debt_Details_L

Note 6 - Long-Term Debt (Details) - Long Term Debt Outstanding (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Note 6 - Long-Term Debt (Details) - Long Term Debt Outstanding [Line Items]	'	'
Less current portion of long-term debt, third party	($10,080)	($5,405)
Long-term debt, third party, net	31,920	34,595
Third Party Debt [Member]	'	'
Note 6 - Long-Term Debt (Details) - Long Term Debt Outstanding [Line Items]	'	'
Total debt, third party	42,000	40,000
Less current portion of long-term debt, third party	-10,080	-5,405
Long-term debt, third party, net	31,920	34,595
Related Party [Member]	'	'
Note 6 - Long-Term Debt (Details) - Long Term Debt Outstanding [Line Items]	'	'
Total debt, third party	15,000	'
Less current portion of long-term debt, third party	-500	'
Long-term debt, third party, net	$14,500	'

Note_6_LongTerm_Debt_Details_M

Note 6 - Long-Term Debt (Details) - Maturities of Debt (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Third Party Debt [Member]	'	'
Note 6 - Long-Term Debt (Details) - Maturities of Debt [Line Items]	'	'
2014	$10,080	'
2015	16,800	'
2016	15,120	'
	42,000	40,000
Related Party [Member]	'	'
Note 6 - Long-Term Debt (Details) - Maturities of Debt [Line Items]	'	'
2014	500	'
2015	2,000	'
2016	2,000	'
2017	10,500	'
	$15,000	'

Note_7_Lease_Obligations_Detai

Note 7 - Lease Obligations (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Leases [Abstract]	'	'	'
Operating Leases, Future Minimum Payments Due	$0.08	'	'
Operating Leases, Rent Expense, Net	$0.20	$0.20	$0.20

Note_8_ShareBased_Compensation2

Note 8 - Share-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	0	198,000	742,234
Options Expiration Term	'	'10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	'	$10.84	$8.67
Allocated Share-based Compensation Expense	$5,300,000	$5,500,000	$4,200,000
Consulting Agreement Purchase Percentage	2.00%	'	'
Additional Stock Option Purchase Percentage	1.00%	'	'
Proceeds from Stock Options Exercised	3,615,000	600,000	620,000
Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Aggregate Fair Value	'	2,100,000	6,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	9,000,000	800,000	500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	7,200,000	5,000,000	3,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	1,900,000	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'328 days	'	'
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	0	0	0
Restricted Stock [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'1 year 109 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)	136,779	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$35.95	'	'
Restricted Stock Vesting Percentage	50.00%	'	'
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Grants In Period Aggregate Fair Value	4,900,000	'	'
Restricted Stock or Unit Expense	1,600,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)	0	'	'
Restricted Stock [Member] | Options Granted to Employees and Directors [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	3,300,000	'	'
Consultant Stock Compensation Expense [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$2,900,000	$1,600,000	$1,100,000
Stock Plan 2010 [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options (in Shares)	2,178,641	'	'
Options granted to Employees, Directors, and Consultants [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	'	$17.95	$13.87
Options Granted to Employees and Directors [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	0	'	'
Options Granted to Consultants [Member]	'	'	'
Note 8 - Share-Based Compensation (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	0	0	'

Note_8_ShareBased_Compensation3

Note 8 - Share-Based Compensation (Details) - Summary of Option Activity (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 29, 2012	Dec. 29, 2011	Dec. 29, 2010
Note 8 - Share-Based Compensation (Details) - Summary of Option Activity [Line Items]	'	'	'	'	'	'
Granted	0	198,000	742,234	'	'	'
Furiex Plan [Member]	'	'	'	'	'	'
Note 8 - Share-Based Compensation (Details) - Summary of Option Activity [Line Items]	'	'	'	'	'	'
Outstanding at January 1	1,644,000	1,512,000	'	1,644,000	1,512,000	839,000
Outstanding at January 1	$12.33	$11.45	'	$12.33	$11.45	$9.11
Granted	'	198,000	742,000	'	'	'
Granted	'	$17.95	$13.87	'	'	'
Exercised	-307,000	-66,000	-68,000	'	'	'
Exercised	$11.77	$9.11	$9.11	'	'	'
Forfeited	-2,000	'	-1,000	'	'	'
Forfeited	$17.80	'	$9.11	'	'	'
Outstanding at December 31	1,335,000	1,644,000	1,512,000	1,644,000	1,512,000	839,000
Outstanding at December 31	$12.45	$12.33	$11.45	$12.33	$11.45	$9.11
Outstanding at December 31	'7 years 73 days	'	'	'	'	'
Outstanding at December 31	$39,460	'	'	'	'	'
Exercisable at December 31	1,120,000	842,000	343,000	'	'	'
Exercisable at December 31	$11.96	$11.44	$10.58	'	'	'
Exercisable at December 31	'7 years 36 days	'	'	'	'	'
Exercisable at December 31	33,646	'	'	'	'	'
Vested or expected to vest at December 31, 2013	1,322,000	'	'	'	'	'
Vested or expected to vest at December 31, 2013	$12.42	'	'	'	'	'
Vested or expected to vest at December 31, 2013	'7 years 73 days	'	'	'	'	'
Vested or expected to vest at December 31, 2013	$39,119	'	'	'	'	'

Note_8_ShareBased_Compensation4

Note 8 - Share-Based Compensation (Details) - Stock Options by Range of Exercise Price (Furiex Plan [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 29, 2012	Dec. 31, 2011	Dec. 29, 2011	Dec. 29, 2010
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'
Options Outstanding - Number Outstanding (in Shares)	1,335	1,644	1,644	1,512	1,512	839
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	'7 years 73 days	'	'	'	'	'
Options Outstanding - Weighted-Average Exercise Price	$12.45	$12.33	$12.33	$11.45	$11.45	$9.11
Options Exercisable - Number Exercisable (in Shares)	1,120	842	'	343	'	'
Options Exercisable - Weighted-Average Exercise Price	$11.96	$11.44	'	$10.58	'	'
Exercise Price Range One [Member]	'	'	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'
Range of Exercise Prices - Lower	$9.11	'	'	'	'	'
Range of Exercise Prices - Upper	$13	'	'	'	'	'
Options Outstanding - Number Outstanding (in Shares)	536	'	'	'	'	'
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	'6 years 6 months	'	'	'	'	'
Options Outstanding - Weighted-Average Exercise Price	$9.11	'	'	'	'	'
Options Exercisable - Number Exercisable (in Shares)	536	'	'	'	'	'
Options Exercisable - Weighted-Average Exercise Price	$9.11	'	'	'	'	'
Exercise Price Range Two [Member]	'	'	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'
Range of Exercise Prices - Lower	$13.01	'	'	'	'	'
Range of Exercise Prices - Upper	$15	'	'	'	'	'
Options Outstanding - Number Outstanding (in Shares)	628	'	'	'	'	'
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	'7 years 219 days	'	'	'	'	'
Options Outstanding - Weighted-Average Exercise Price	$13.81	'	'	'	'	'
Options Exercisable - Number Exercisable (in Shares)	498	'	'	'	'	'
Options Exercisable - Weighted-Average Exercise Price	$13.98	'	'	'	'	'
Exercise Price Range Three [Member]	'	'	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'
Range of Exercise Prices - Lower	$15.01	'	'	'	'	'
Range of Exercise Prices - Upper	$17	'	'	'	'	'
Options Outstanding - Number Outstanding (in Shares)	2	'	'	'	'	'
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	'8 years	'	'	'	'	'
Options Outstanding - Weighted-Average Exercise Price	$16.71	'	'	'	'	'
Options Exercisable - Number Exercisable (in Shares)	1	'	'	'	'	'
Options Exercisable - Weighted-Average Exercise Price	$16.71	'	'	'	'	'
Exercise Price Range Four [Member]	'	'	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'	'	'
Range of Exercise Prices - Lower	$17.01	'	'	'	'	'
Range of Exercise Prices - Upper	$18.22	'	'	'	'	'
Options Outstanding - Number Outstanding (in Shares)	169	'	'	'	'	'
Options Outstanding - Weighted-Average Remaining Contractual Life (Years)	'8 years 73 days	'	'	'	'	'
Options Outstanding - Weighted-Average Exercise Price	$17.93	'	'	'	'	'
Options Exercisable - Number Exercisable (in Shares)	85	'	'	'	'	'
Options Exercisable - Weighted-Average Exercise Price	$18.06	'	'	'	'	'

Note_8_ShareBased_Compensation5

Note 8 - Share-Based Compensation (Details) - Unvested Options (Furiex Plan [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Furiex Plan [Member]	'
Note 8 - Share-Based Compensation (Details) - Unvested Options [Line Items]	'
Shares	802
Weighted-Average Grant Date Fair Value	$8.47
Vested	-585
Vested	$8.09
Forfeited	-1
Forfeited	$10.87
Shares	216
Weighted-Average Grant Date Fair Value	$9.47

Note_8_ShareBased_Compensation6

Note 8 - Share-Based Compensation (Details) - Assumptions Used in Estimating Fair Value of Options Granted to Employees and Directors (Furiex Plan [Member], Options Granted to Employees and Directors [Member])	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Minimum [Member]	'	'
Note 8 - Share-Based Compensation (Details) - Assumptions Used in Estimating Fair Value of Options Granted to Employees and Directors [Line Items]	'	'
Expected term (years)	'5 years 6 months	'5 years 6 months
Risk-free interest rate (%)	0.84%	1.10%
Expected volatility (%)	68.28%	65.09%
Maximum [Member]	'	'
Note 8 - Share-Based Compensation (Details) - Assumptions Used in Estimating Fair Value of Options Granted to Employees and Directors [Line Items]	'	'
Expected term (years)	'6 years	'6 years
Risk-free interest rate (%)	1.15%	2.18%
Expected volatility (%)	68.96%	69.97%

Note_8_ShareBased_Compensation7

Note 8 - Share-Based Compensation (Details) - Assumptions Used in Estimating Fair Value of Option Granted to Consultants (Furiex Plan [Member], Options Granted to Consultants [Member])	12 Months Ended
	Dec. 31, 2011
Furiex Plan [Member] | Options Granted to Consultants [Member]	'
Note 8 - Share-Based Compensation (Details) - Assumptions Used in Estimating Fair Value of Option Granted to Consultants [Line Items]	'
Expected term (years)	'10 years
Risk-free interest rate (%)	1.92%
Expected volatility (%)	67.05%

Note_8_ShareBased_Compensation8

Note 8 - Share-Based Compensation (Details) - A Summary of Restricted Stock Activity (USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Stock [Member] | Furiex Plan [Member]	'
Note 8 - Share-Based Compensation (Details) - A Summary of Restricted Stock Activity [Line Items]	'
Granted	137,000
Granted	$35.95
Outstanding at December 31, 2013	137,000
Outstanding at December 31, 2013	$35.95
Vested or expected to vest at December 31, 2013	137,000
Vested or expected to vest at December 31, 2013	$35.95
Restricted Stock [Member]	'
Note 8 - Share-Based Compensation (Details) - A Summary of Restricted Stock Activity [Line Items]	'
Granted	136,779
Furiex Plan [Member]	'
Note 8 - Share-Based Compensation (Details) - A Summary of Restricted Stock Activity [Line Items]	'
Vested or expected to vest at December 31, 2013	1,322,000

Note_8_ShareBased_Compensation9

Note 8 - Share-Based Compensation (Details) - A Summary Unvested Restricted Stock (Unvested Restricted Stock [Member], Furiex Restricted Stock Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Unvested Restricted Stock [Member] | Furiex Restricted Stock Plan [Member]	'
Note 8 - Share-Based Compensation (Details) - A Summary Unvested Restricted Stock [Line Items]	'
Unvested at	137,000
Unvested at	$35.95
Granted	137,000
Granted	$35.95

Note_9_Income_Taxes_Details

Note 9 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 9 - Income Taxes (Details) [Line Items]	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	'
Deferred Tax Liabilities, Net	$242,000	$220,000
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	149,200,000	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	43,100,000	'
Priligy [Member]	'	'
Note 9 - Income Taxes (Details) [Line Items]	'	'
Deferred State and Local Income Tax Expense (Benefit)	300,000	'
Stock Compensation Tax Deductions [Member]	'	'
Note 9 - Income Taxes (Details) [Line Items]	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	6,700,000	'
Finite-Lived Intangible Assets [Member]	'	'
Note 9 - Income Taxes (Details) [Line Items]	'	'
Deferred Tax Liabilities, Net	$200,000	$200,000

Note_9_Income_Taxes_Details_Re

Note 9 - Income Taxes (Details) - Reconciliation of Statutory Federal Income Tax to Provision for Income Tax (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Statutory Federal Income Tax to Provision for Income Tax [Abstract]	'	'	'
Effective tax rate	-1.20%	0.00%	0.00%
Statutory rate of 35%	($10,264)	($14,998)	($17,138)
State taxes, net of federal benefit	-13	-121	-284
Permanent and other differences	-100	377	371
Change in valuation allowance	10,496	13,934	17,065
Adjustment to deferred state tax rate	229	822	'
Provision for income taxes	$348	$14	$14

Note_9_Income_Taxes_Details_Co

Note 9 - Income Taxes (Details) - Components of the Current and Long Term Deferred Tax Assets (Liabilities) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Note 9 - Income Taxes (Details) - Components of the Current and Long Term Deferred Tax Assets (Liabilities) [Line Items]	'	'
Accrued expenses	$382	$360
Total long-term deferred tax asset (liability)	-242	-220
Depreciation and amortization	2,259	2,283
Shared based compensation	4,261	2,567
Future benefit of carry forward losses	51,470	42,688
Current [Member]	'	'
Note 9 - Income Taxes (Details) - Components of the Current and Long Term Deferred Tax Assets (Liabilities) [Line Items]	'	'
Valuation allowance	-382	-360
Noncurrent [Member]	'	'
Note 9 - Income Taxes (Details) - Components of the Current and Long Term Deferred Tax Assets (Liabilities) [Line Items]	'	'
Valuation allowance	($58,232)	($47,758)

Note_10_Employee_Savings_Plan_

Note 10 - Employee Savings Plan (Details) (Furiex Plan [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Furiex Plan [Member]	'	'	'
Note 10 - Employee Savings Plan (Details) [Line Items]	'	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	100.00%	'	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	'	'
Pension Contributions	$0.15	$0.15	$0.14

Note_11_Commitments_and_Contin1

Note 11 - Commitments and Contingencies (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 30, 2012

Jul. 30, 2012

Jul. 30, 2012

Jul. 30, 2012

Dec. 31, 2013

Jul. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Jul. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Priligy [Member]

JNJ-Q2 [Member]

MuDelta [Member]

JNJ-Q2 and MuDelta [Member]

Janssen [Member]

Janssen [Member]

Janssen [Member]

Janssen [Member]

Janssen [Member]

Janssen [Member]

Menarini [Member]

Menarini [Member]

Menarini [Member]

Menarini [Member]

Lilly [Member]

Janssen [Member]

Janssen [Member]

Janssen [Member]

Paid Within 45 Days Of Closing [Member]

Due Within 10 Business Days of the Beginning of the Following Two Successive Calendar Quarters [Member]

On-Going Clinical Study Costs [Member]

Out Of Pocket Expenses [Member]

On-Going Clinical Study Costs [Member]

Upfront Payment [Member]

Regulatory Milestone Payments [Member]

On-Going Clinical Study Costs [Member]

Sales Based Milestones [Member]

Note 11 - Commitments and Contingencies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Collaborations

4

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Collaboration Agreements That Involve Potential Future Expenditures

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Payments Owed For Transition Services

'

'

'

'

'

'

'

'

'

'

'

'

'

$15,000,000

'

'

'

'

'

Payments For Transition Services

'

'

3,750,000

'

'

'

'

'

7,500,000

3,750,000

'

'

'

'

'

'

'

'

'

Potential Obligation

'

'

'

'

'

'

'

'

'

'

19,000,000

1,000,000

'

'

'

'

'

'

'

Payments Received Under License Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

10,000,000

'

'

'

Licenses Revenue

'

45,000,000

20,000,000

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments Received And Paid Net Basis

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential Receipts Per Licence Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,000,000

40,000,000

'

Payment Received And Paid For On Going Clinical Studies

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Liabilities, Current

5,302,000

5,302,000

10,230,000

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

Potential Royalty Obligation Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

Minimum Sales Threshold For Potential Royalty Obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000,000

Royalty Payment Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The term of the license agreement with Lilly (and the period during which the Company or Menarini must pay Lilly royalties in a particular country) will end, on a country-by-country basis, upon the later of (i) the last to expire valid patent claim licensed to Lilly in that country, (ii) the expiration of data exclusivity in that country, or (iii) the tenth anniversary of the first date of sale of Priligy in that country.

Potential Regulatory Obligation Payments

'

'

'

'

'

50,000,000

45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Potential Sales Based Milestone Payments

'

'

'

'

'

'

'

$75,000,000

'

'

'

'

'

'

'

'

'

'

'

Sales Based Royalty Payment Period

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Note_12_Fair_Value_Measurement2

Note 12 - Fair Value Measurements (Details) - Fair Value of Assets and Liabilities Measured on a Recurring Basis (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
In Thousands, unless otherwise specified
Note 12 - Fair Value Measurements (Details) - Fair Value of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'	'	'	'
Total Carrying Value	$29,153	$25,718	$33,628	$82,030
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]	'	'	'	'
Note 12 - Fair Value Measurements (Details) - Fair Value of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'	'	'	'
Fair Value Measurements	16,563	23,727	'	'
Money Market Funds [Member]	'	'	'	'
Note 12 - Fair Value Measurements (Details) - Fair Value of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'	'	'	'
Total Carrying Value	16,563	23,727	'	'
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'	'	'
Note 12 - Fair Value Measurements (Details) - Fair Value of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'	'	'	'
Investments - money market mutual funds	'	7,500	'	'
Money Market Funds [Member]	'	'	'	'
Note 12 - Fair Value Measurements (Details) - Fair Value of Assets and Liabilities Measured on a Recurring Basis [Line Items]	'	'	'	'
Investments - money market mutual funds	'	$7,500	'	'

Note_13_Segment_Information_De

Note 13 - Segment Information (Details)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Number of Reportable Segments	1

Note_14_Quarterly_Financial_Da2

Note 14 - Quarterly Financial Data (unaudited) (Details) (USD $)	12 Months Ended		3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Sep. 30, 2012	Mar. 31, 2013	Mar. 31, 2013	Sep. 30, 2013	Dec. 31, 2013
			European Medicines Agency Milestone Revenue [Member]	Menarini - Priligy License Milestone Revenue [Member]	Takeda - FDA Product Approval Milestone Revenue [Member]	Menarini - Launch of Priligy Milestone Revenue [Member]	Takeda - European Marketing Authorization Milestone Revenue [Member]	Menarini - Launch of Priligy in UK Milestone Revenue [Member]
Note 14 - Quarterly Financial Data (unaudited) (Details) [Line Items]	'	'	'	'	'	'	'	'
Licenses Revenue	$45,000	$20,000	$10,000	$10,000	$25,000	$5,000	$10,000	$5,000

Note_14_Quarterly_Financial_Da3

Note 14 - Quarterly Financial Data (unaudited) (Details) - Quarterly Financial Data (unaudited) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Quarterly Financial Data (unaudited) [Abstract]	'		'		'		'		'		'		'		'		'		'		'
Total revenue (a)	$13,134	[1]	$15,550	[1]	$2,990	[1]	$39,325	[1]	$9,211	[2]	$15,577	[2]	$13,075	[2]	$2,645	[2]	$70,999	[1]	$40,508	[2]	$4,490
Operating loss	-4,638		-7,550		-22,315		10,067		-7,926		-2,452		-20,489		-9,477		-24,438		-40,344		-48,556
Net loss	($6,500)		($8,683)		($23,453)		$8,966		($9,052)		($3,286)		($20,769)		($9,758)		($29,673)		($42,865)		($48,981)
Net income (loss) per basic share (in Dollars per share)	($0.63)		($0.85)		($2.32)		$0.89		'		'		'		'		($2.92)		'		'
Net income (loss) per diluted share (in Dollars per share)	($0.63)		($0.85)		($2.32)		$0.82		'		'		'		'		($2.92)		'		'
Net loss per basic and diluted share (in Dollars per share)	'		'		'		'		($0.90)		($0.33)		($2.09)		($0.98)		($2.92)		($4.29)		($4.96)
[1]	The first quarter of 2013 includes a $25.0 million regulatory milestone from Takeda with respect to the FDA approval of three new alogliptin-related products in January 2013 and a $5.0 million milestone from Menarini upon the launch of Priligy in France in March 2013. The third quarter of 2013 includes a $10.0 million milestone from Takeda upon the European Marketing Authorization of alogliptin and related products in September 2013. The fourth quarter of 2013 includes a $5.0 million milestone from Menarini upon the launch of Priligy in the United Kingdom in October 2013.
[2]	The second quarter of 2012 includes a $10.0 million regulatory milestone related to the acceptance of the submission of a Marketing Authorization Application by the European Medicines Agency for alogliptin in May 2012. The third quarter of 2012 includes a $10.0 million launch-based milestone related to the Priligy license agreement with Menarini.